HUP0400645A2 - NMDA-receptor agonistát tartalmazó gyógyászati készítmények - Google Patents

NMDA-receptor agonistát tartalmazó gyógyászati készítmények

Info

Publication number
HUP0400645A2
HUP0400645A2 HU0400645A HUP0400645A HUP0400645A2 HU P0400645 A2 HUP0400645 A2 HU P0400645A2 HU 0400645 A HU0400645 A HU 0400645A HU P0400645 A HUP0400645 A HU P0400645A HU P0400645 A2 HUP0400645 A2 HU P0400645A2
Authority
HU
Hungary
Prior art keywords
disease
contain
dementia
preparations
hydroxy4
Prior art date
Application number
HU0400645A
Other languages
English (en)
Inventor
Jinyang Hong
Yesook Kim
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of HUP0400645A2 publication Critical patent/HUP0400645A2/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/02Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Addiction (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A találmány olyan, stabil gyógyászati készítményekre vonatkozik,amelyek hatóanyagként egy N-metil-D-aszparaginsav (NMDA) receptorantagonistát, azaz (1S,2S)-1-(4-hidroxifenil)-2(4-hidroxi4-fenilpiperidin-l-il)-1-propanolt tartalmaznak. A találmány szerintigyógyászati készítmények felhasználhatók sztrók, a gerincvelősérülései, traumás agysérülések, multiinfarktusos demencia, a központiidegrendszer degeneratív megbetegedései, így például Alzheimer-kór,Alzheimer-típusú öregkori demencia, Huntington-kór, Parkinson-kór,epilepszia, amiotrófiás egyoldali szklerózis, fájdalom, AIDSkövetkeztében fellépő demencia, pszichotikus állapotok, kábítószerhezvaló hozzászokás, migrén, hipoglükémia, azaz alacsony vércukorszint,szorongásos állapotok, vizelet-visszatartási nehézségek és a központiidegrendszerben végrehajtott sebészeti beavatkozás, úgynevezettnyitottszíves sebészeti beavatkozás vagy bármely olyan más eljáráskövetkeztében fellépő ischémiás esemény kezelésére, amelynek során akardiovaszkuláris rendszer funkciója sérülést szenved. A találmányszerinti készítményekre az jellemző, hogy farmakológiailag hatásosmennyiségben (1S,2S)-1-(4-hidroxifenil)-2-(4-hidroxi4-fenilpiperidin-l-il)-1-propanolt vagy ennek gyógyászatilag elfogadható sóját és vizettartalmaznak, mimellett az ilyen készítméryek kevesebb, mintkörülbelül 2 p.p.m. mennyiségű szabad réziont és kevesebb mintkörülbelül 2 p.p.m. szabad vasiont tartalmaznak. Ó
HU0400645A 2000-12-13 2001-12-05 NMDA-receptor agonistát tartalmazó gyógyászati készítmények HUP0400645A2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25537200P 2000-12-13 2000-12-13
PCT/IB2001/002359 WO2002047685A2 (en) 2000-12-13 2001-12-05 Nmda receptor agonist pharmaceutical compositions

Publications (1)

Publication Number Publication Date
HUP0400645A2 true HUP0400645A2 (hu) 2004-06-28

Family

ID=22968017

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0400645A HUP0400645A2 (hu) 2000-12-13 2001-12-05 NMDA-receptor agonistát tartalmazó gyógyászati készítmények

Country Status (42)

Country Link
US (2) US6635270B2 (hu)
EP (1) EP1347760B1 (hu)
JP (1) JP2004515529A (hu)
KR (1) KR100533407B1 (hu)
CN (1) CN1273135C (hu)
AP (1) AP1235A (hu)
AR (1) AR035607A1 (hu)
AT (1) ATE296629T1 (hu)
AU (2) AU2002218454B2 (hu)
BG (1) BG107788A (hu)
BR (1) BR0116085A (hu)
CA (1) CA2431172A1 (hu)
CZ (1) CZ20031543A3 (hu)
DE (1) DE60111265T2 (hu)
DO (1) DOP2001000300A (hu)
DZ (1) DZ3484A1 (hu)
EA (1) EA006489B1 (hu)
EC (1) ECSP034655A (hu)
EE (1) EE200300284A (hu)
ES (1) ES2239648T3 (hu)
GE (1) GEP20053568B (hu)
HK (1) HK1059575A1 (hu)
HR (1) HRP20030473A2 (hu)
HU (1) HUP0400645A2 (hu)
IL (1) IL155810A0 (hu)
IS (1) IS6811A (hu)
MA (1) MA26970A1 (hu)
MX (1) MXPA03005257A (hu)
NO (1) NO20032678L (hu)
NZ (1) NZ525742A (hu)
OA (1) OA12414A (hu)
PA (1) PA8534901A1 (hu)
PE (1) PE20020710A1 (hu)
PL (1) PL362080A1 (hu)
PT (1) PT1347760E (hu)
SK (1) SK6982003A3 (hu)
TN (1) TNSN01173A1 (hu)
UA (1) UA73619C2 (hu)
UY (1) UY27068A1 (hu)
WO (1) WO2002047685A2 (hu)
YU (1) YU41103A (hu)
ZA (1) ZA200303892B (hu)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2362560C2 (ru) 2003-04-08 2009-07-27 Проджиникс Фармасьютикалз, Инк. Фармацевтическая препаративная форма
TW200800959A (en) * 2005-06-10 2008-01-01 Wyeth Corp Piperazine-piperidine antagonists and agonists of the 5-HT1a receptor
TW200811144A (en) * 2006-06-09 2008-03-01 Wyeth Corp Crystalline forms of 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline
TW200808741A (en) * 2006-06-09 2008-02-16 Wyeth Corp 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline hydrochloric acid salts
TW200808740A (en) * 2006-06-09 2008-02-16 Wyeth Corp Succinate salts of 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline and crystalline forms thereof
TW200831096A (en) * 2006-11-28 2008-08-01 Wyeth Corp Metabolites of 5-Fluoro-8-{4-[4-(6-methoxyquinolin-8-yl)piperazin-1-yl]piperidin-1-yl} quinoline and methods of preparation and uses thereof
TW200901974A (en) 2007-01-16 2009-01-16 Wyeth Corp Compounds, compositions, and methods of making and using them
CN101317844B (zh) * 2007-06-08 2010-11-17 章劲夫 化合物(+)-5-甲基-10,11-二氢-5H-二苯并〔a,d〕环庚烯-5,10-亚胺在制备避孕药物中的应用
MX2011003015A (es) 2008-09-18 2011-11-18 Univ Northwestern Moduladores del receptor de n-metil-d-aspartato, y usos de los mismos.
US8951968B2 (en) 2009-10-05 2015-02-10 Northwestern University Methods of treating depression and other related diseases
US9101612B2 (en) 2010-02-11 2015-08-11 Northwestern University Secondary structure stabilized NMDA receptor modulators and uses thereof
KR101692275B1 (ko) 2010-02-11 2017-01-04 노오쓰웨스턴 유니버시티 2차 구조 안정화된 nmda 수용체 조절제 및 그의 용도
CN102586243A (zh) * 2012-03-08 2012-07-18 中国人民解放军军事医学科学院放射与辐射医学研究所 一种预防电磁辐射致脑损伤的标志物
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神分裂病を処置するための方法および組成物
WO2014120800A1 (en) 2013-01-29 2014-08-07 Naurex, Inc. Spiro-lactam nmda receptor modulators and uses thereof
LT3514158T (lt) 2013-01-29 2023-02-10 Aptinyx Inc. Spirolaktaminiai nmda receptoriaus moduliatoriai ir jų panaudojimas
EA032153B1 (ru) 2013-01-29 2019-04-30 Аптиникс Инк. Спиролактамные модуляторы nmda-рецептора и их применение
BR112015018092A2 (pt) 2013-01-29 2017-07-18 Naurex Inc moduladores de receptor de nmda de espiro-lactama e usos dos mesmos
EA201591404A1 (ru) 2013-01-29 2016-01-29 Аптиникс Инк. Спиролактамные модуляторы рецептора nmda и их применение
WO2015099381A1 (ko) * 2013-12-23 2015-07-02 주식회사 삼양바이오팜 팔로노세트론을 함유하는 약학 조성물
MX2018014202A (es) 2016-05-19 2019-06-20 Aptinyx Inc Moduladores del receptor espiro-lactama n-metil-d-aspartato y usos de los mismos.
WO2017201285A1 (en) 2016-05-19 2017-11-23 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
AU2017305240B2 (en) 2016-08-01 2021-12-09 Aptinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
AU2017306152A1 (en) 2016-08-01 2019-01-31 Aptinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
MX2019001322A (es) 2016-08-01 2019-09-11 Aptinyx Inc Moduladores del receptor nmda spiro-lactam y bis-spiro-lactam y uso de los mismos.
BR112019001923A2 (pt) 2016-08-01 2019-05-14 Aptinyx Inc. moduladores de nmda de espiro-lactama e métodos de sua utilização
PE20190500A1 (es) 2016-08-01 2019-04-10 Aptinyx Inc Moduladores del receptor nmda spiro-lactam y uso de los mismos
JP7210599B2 (ja) 2018-01-31 2023-01-23 アプティニックス インコーポレイテッド スピロラクタム系nmda受容体修飾因子およびその使用
US12012413B2 (en) 2019-11-11 2024-06-18 Tenacia Biotechnology (Hong Kong) Co., Limited Methods of treating painful diabetic peripheral neuropathy

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5272160A (en) 1989-05-17 1993-12-21 Pfizer Inc 2-piperidino-1-alkanol derivatives as antiischemic agents
US5710168A (en) 1991-10-23 1998-01-20 Pfizer Inc. 2-piperidino-1-alkanol derivatives as neuroprotective agents
UA59341C2 (uk) * 1995-08-11 2003-09-15 Пфайзер, Інк. (1s,2s)-1-(4-гідроксифеніл)-2-(4-гідрокси-4-фенілпіперидин-1-іл)-1-пропанолметансульфонат тригідрат
TW450807B (en) * 1995-09-15 2001-08-21 Pfizer Pharmaceutical compositions for treating tinnitus comprising neuroprotective agents

Also Published As

Publication number Publication date
DE60111265T2 (de) 2006-05-04
YU41103A (sh) 2006-05-25
PA8534901A1 (es) 2002-08-26
KR20030070060A (ko) 2003-08-27
EA006489B1 (ru) 2005-12-29
MXPA03005257A (es) 2003-09-25
NZ525742A (en) 2005-07-29
ATE296629T1 (de) 2005-06-15
UY27068A1 (es) 2002-07-31
TNSN01173A1 (fr) 2005-11-10
MA26970A1 (fr) 2004-12-20
JP2004515529A (ja) 2004-05-27
ECSP034655A (es) 2003-07-25
CN1273135C (zh) 2006-09-06
OA12414A (en) 2006-04-18
EA200300514A1 (ru) 2003-10-30
US20020111366A1 (en) 2002-08-15
BR0116085A (pt) 2003-12-23
DE60111265D1 (de) 2005-07-07
ES2239648T3 (es) 2005-10-01
AR035607A1 (es) 2004-06-16
NO20032678D0 (no) 2003-06-12
BG107788A (bg) 2004-01-30
AP1235A (en) 2004-01-06
GEP20053568B (en) 2005-07-11
PL362080A1 (en) 2004-10-18
IL155810A0 (en) 2003-12-23
DOP2001000300A (es) 2002-05-30
SK6982003A3 (en) 2004-08-03
US6635270B2 (en) 2003-10-21
CZ20031543A3 (cs) 2004-06-16
CA2431172A1 (en) 2002-06-20
WO2002047685A3 (en) 2002-08-15
EP1347760B1 (en) 2005-06-01
CN1479617A (zh) 2004-03-03
HK1059575A1 (en) 2004-07-09
DZ3484A1 (fr) 2002-06-20
AU2002218454B2 (en) 2005-10-27
HRP20030473A2 (en) 2005-04-30
UA73619C2 (en) 2005-08-15
AU1845402A (en) 2002-06-24
KR100533407B1 (ko) 2005-12-02
NO20032678L (no) 2003-06-12
US20040039022A1 (en) 2004-02-26
AP2001002376A0 (en) 2001-12-31
EP1347760A2 (en) 2003-10-01
PE20020710A1 (es) 2002-08-09
PT1347760E (pt) 2005-09-30
EE200300284A (et) 2003-10-15
WO2002047685A2 (en) 2002-06-20
ZA200303892B (en) 2004-05-20
IS6811A (is) 2003-05-08

Similar Documents

Publication Publication Date Title
HUP0400645A2 (hu) NMDA-receptor agonistát tartalmazó gyógyászati készítmények
ES2284740T3 (es) Carboxilato de terfenadina y el tratamiento de la irritacion cutanea.
CA2545503C (en) Use of sphingosine-1-phosphate (s1p) receptor agonists for the treatment of brain degenerative diseases
WO2002042462A3 (en) Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
CA2433585A1 (en) Pharmaceutical compositions containing donepezil hydrochloride
BG106251A (en) Levodopa (carbidopa) entacapone pharmaceutical preparation
MXPA04005444A (es) Ureas de 2-aminobenzotiazoles como moduladores de adenosina.
HK1049448A1 (en) Improved transdermal therapeutic system for the treatment of parkinson's disease
UA92181C2 (ru) Производные пиримидина и их применение в терапии и в производстве лекарственного средства для предотвращения и/или лечения болезни альцгеймера
EA200970148A1 (ru) Фармацевтический состав, содержащий донепезил
BR9916361A (pt) Forma de dosagem de tabletes de liberação controlada, formulação de tablete de liberação controlada, composição granular para prensagem em uma forma de dosagem de tablete de liberação controlada, e, métodos para preparar uma composição granular, para preparar uma forma de dosagem de tabletes de liberação controlada de divalproex sódio e para tratar epilepsia
TW200944198A (en) Crystalline form of a (3S)-aminomethyl-5-methyl-hexanoic acid prodrug and methods of use
KR20170083509A (ko) 바레니클린 또는 이의 약학적으로 허용가능한 염을 함유하는 맛 차폐된 구강 투여용 약학 제제
TW201116273A (en) Co-crystals of tramadol and coxibs
HK1087039A1 (en) Use of biphosphonate in preparing medical kit and a kit used for increasing bone mass
CN105792821A (zh) 包含1-茚满硫酰胺衍生物的疼痛治疗剂和/或预防剂
KR100259567B1 (ko) 신경변성 질환 치료용 1-페닐-2-(2-피리디닐)에틸아민 에난티오머
JP2004524357A5 (hu)
TWI290831B (en) Agent for treating Parkinson's disease comprising astrocyte function-improving agent as active ingredient
AP2001002119A0 (en) Sertraline oral concentrate.
Maclennan et al. Ginkgolide B accelerates vestibular compensation of spontaneous ocular nystagmus in guinea pig following unilateral labyrinthectomy
WO2008057599A3 (en) Methods for the treatment of abeta related disorders and compositions therefor
CN109966278B (zh) 草酰苹果酸在制备治疗神经细胞损伤的药物中的应用
MY131159A (en) New pharmaceutical compositions containing epinastine and pseudoephedrine
JPH0840902A (ja) 末梢神経障害および中枢神経変性疾患の治療に有用な医薬組成物

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees